首页   >  
Angiogenesis/Protein Tyrosine Kinase
  • Jak/Stat Pathway
  >  
EGFR

所有产品分类

所有产品

信号通路

研究领域

天然产物

抗体

多肽

催化剂

杂质对照品

医药中间体

基础原料

EGFR

结构式 货号 产品名称 CAS号
AZ7550 hydrochloride 结构式
BCP43207 AZ7550 hydrochloride 2309762-40-9
AZ-7550 is a metabolite of Osimertinib.
AST5902 结构式
BCP39664 AST5902 AST5902
Alflutinib is mainly metabolized via CYP3A4 to form its active metabolite AST5902.
JND3229 结构式
BCP38649 JND3229 2260886-64-2
JND3229 is a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy (IC50 = 5.8 nM).
Almonertinib 结构式
BCP38312 阿美替尼 1899921-05-1
Almonertinib is an EGFR tyrosine kinase inhibitor. Upon administration, HS-10296 binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, inhibits the tyrosine kinase activity of EGFR T790M, prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells.
Epertinib hydrochloride 结构式
BCP37982 Epertinib hydrochloride 2071195-74-7
Epertinib hydrochloride is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4. It shows potent antitumor activity.
TX1-85-1 结构式
BCP37896 TX1-85-1 1603845-32-4
TX1-85-1 is an inhibitor of the epidermal growth factor receptor tyrosine kinase ErbB3 (IC50 = 23 nM).
PD089828 结构式
BCP37851 PD089828 179343-17-0
PD-089828 is an ATP competitive inhibitor of FGFR-1, PDGFR-β and EGFR (IC50s=0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of c-Src tyrosine kinase (IC50=0.18 µM). PD-089828 also inhibits MAPK with an IC50 of 7.1 µM. PD-089828 inhibits PDGF-, EGF- and bFGF-mediated tyrosine kinase receptor autophosphorylation in vitro. PD-089828 has a long-lasting cellular activity.
EGFR-IN-8 结构式
BCP37628 EGFR-IN-8 2407957-87-1
EGFR-IN-8 is a dual EGFR and c-Met inhibitor, compound 48.
BDTX-189 结构式
BCP37532 BDTX-189 2414572-47-5
BDTX-189 is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, includes EGFR/HER2 exon 20 insertion mutants. BDTX-189 shows KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity.
CH7233163 结构式
BCP37295 CH7233163 CH7233163
CH7233163 overcomes osimertinib resistant EGFR-Del19/T790M/C797S mutation
123下一页末页共 135 条记录 1 / 14 页 
2853530913